10-Q: Clover Health Q3 Loss Widens, PPO Star Rating Drops to 3.5 Stars

Clover Health reported a significantly wider net loss in Q3 2025 despite revenue growth, alongside a critical downgrade of its primary Medicare Advantage PPO plans to 3.5 Stars for 2026.

Summary

• Total revenues increased by 50.1% to $496.65 million for the three months ended September 30, 2025, compared to $330.99 million in the prior year period, primarily driven by a 35% growth in average members.
• Net loss widened significantly to $24.38 million for the three months ended September 30, 2025, from $9.16 million in the same period last year, representing a 166.3% increase.
• Net medical claims incurred surged by 69.5% to $423.47 million for the three months ended September 30, 2025, outpacing revenue growth and leading to a higher net benefits expense ratio of 93.5% (up from 82.8%).
• Adjusted EBITDA decreased by 89.0% to $2.11 million for the three months ended September 30, 2025, compared to $19.26 million in the prior year period.
• Adjusted Net income from continuing operations fell by 91.0% to $1.71 million for the three months ended September 30, 2025, from $18.92 million in the prior year period.
• The company's PPO Medicare Advantage plans received a downgraded CMS Star rating of 3.5 Stars for 2026, which will impact payment year 2027, while its HMO plan increased to 4.0 Stars.
• Cash provided by operating activities from continuing operations decreased substantially to $1.22 million for the nine months ended September 30, 2025, from $129.54 million in the prior year period.
• Unfavorable prior period claims development of $9.6 million was recognized during the nine months ended September 30, 2025, compared to a favorable development of $31.5 million in the prior year period.
• Launched Counterpart Health, Inc., a new Software-as-a-Service (SaaS) and Tech Enabled Services Solution, to extend its AI-powered care management platform to external payors and providers.
• The SEC investigation related to certain disclosures and aspects of the business concluded on September 26, 2024, with no enforcement action recommended against the company.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant widening of net losses, a substantial decline in Adjusted EBITDA and Adjusted Net Income, and a worsening benefits expense ratio. The critical downgrade of the PPO Medicare Advantage Star Rating, which affects the majority of members and future payments, is a major negative factor. While revenue and membership grew, the underlying profitability and cash generation deteriorated significantly.

Positives

• Total revenues increased by 50.1% for the three months and 38.9% for the nine months ended September 30, 2025, driven by strong membership growth.
• Average members increased by approximately 35% for the three months and 32% for the nine months ended September 30, 2025, reaching 109,226 members at period end.
• Other income more than doubled, increasing by 108.4% to $17.52 million for the three months ended September 30, 2025, primarily due to an increase in the fair value of equity investments.
• The SEC investigation related to the Hindenburg Article concluded on September 26, 2024, with the Staff not intending to recommend an enforcement action against the company.
• A securities class action lawsuit was settled for $22 million on October 3, 2023, with $19.5 million funded by insurance proceeds, resolving a significant legal contingency.
• The company launched Counterpart Health, Inc., a new SaaS offering, to expand the reach of its Clover Assistant technology to external payors and providers, representing a potential high-margin business opportunity.
• Salaries and benefits decreased by 12.4% for the three months ended September 30, 2025, primarily due to a decrease in variable incentive bonus accruals.
• The HMO Medicare Advantage plan's CMS Star rating increased to 4.0 Stars for 2026.
• Claims processing speed improved, with the ratio of current year medical claims paid as a percentage of current year Net medical claims incurred at 88.5% for the nine months ended September 30, 2025, up from 79.7% in the prior year.

Negatives

• Net loss from continuing operations widened by 177.5% to $24.38 million for the three months ended September 30, 2025, compared to $8.79 million in the prior year period.
• Net medical claims incurred increased by 69.5% for the three months and 51.3% for the nine months ended September 30, 2025, significantly outpacing premium growth.
• The net benefits expense ratio worsened to 93.5% for the three months and 89.4% for the nine months ended September 30, 2025, from 82.8% and 80.6% respectively in the prior year periods.
• Adjusted EBITDA decreased by 89.0% to $2.11 million for the three months and 27.7% to $45.03 million for the nine months ended September 30, 2025.
• Adjusted Net income from continuing operations decreased by 91.0% to $1.71 million for the three months and 28.1% to $43.74 million for the nine months ended September 30, 2025.
• The CMS Star rating for the company's PPO Medicare Advantage plans, which cover over 97% of its insurance members, decreased to 3.5 Stars for 2026, impacting payment year 2027.
• Net cash provided by operating activities from continuing operations decreased dramatically to $1.22 million for the nine months ended September 30, 2025, from $129.54 million in the prior year.
• Unfavorable prior period claims development of $9.6 million was recognized for the nine months ended September 30, 2025, contrasting with a favorable development of $31.5 million in the prior year.
• General and administrative expenses increased by 39.1% for the three months and 19.3% for the nine months ended September 30, 2025, driven by higher professional and broker fees.

Risks

• Expectations regarding results of operations, financial condition, and cash flows may not be met.
• Ability to maintain and increase adoption and use of Clover Assistant, including the expansion of Counterpart Assistant, is uncertain.
• Successfully entering new service markets and managing operations presents challenges.
• Trends and challenges in the competitive and rapidly changing healthcare market could adversely affect the business.
• Any current, pending, or future legislation, regulations, or policies, including the ACA, Medicare rules, and medical loss ratios, could negatively impact revenue, profit margins, cash flows, and business.
• The CMS's intention to significantly increase the volume of Risk Adjustment Data Validation (RADV) audits could lead to adverse financial impacts.
• Ability to effectively manage the beneficiary base and provider network is crucial for performance.
• Maintaining or improving Star Ratings or otherwise improving the financial performance of the business is a key challenge, especially with the PPO downgrade.
• Developing new features and functionality that meet market needs and achieve market acceptance is essential for growth.
• Ability to retain and hire necessary employees and staff operations appropriately is critical.
• The timing and amount of certain investments in growth may not yield expected returns.
• The outcome of any known and unknown litigation and regulatory proceedings could be adverse.
• Fluctuations in the price of Class A common stock and continued compliance with Nasdaq's listing requirements are ongoing concerns.
• Ability to maintain, protect, and enhance intellectual property is vital for competitive advantage.
• General economic conditions and uncertainty, persistent high inflation, and fluctuating interest rates pose financial risks.
• Incurred but not reported claims estimates are inherently difficult and subject to significant judgment, with actual outcomes potentially deviating from assumptions due to changes in economic conditions, government healthcare policy, medical technology, treatment patterns, and average lifespan.

Future Outlook

The company anticipates continued growth in its Medicare Advantage plans and aims to expand the reach of its Clover Assistant technology through its new Counterpart Health SaaS offering. However, the downgrade of its PPO Medicare Advantage plans to 3.5 Stars for 2026 is expected to negatively affect payment year 2027, posing a significant challenge to future financial performance. The company also acknowledges the impact of changes arising from the Inflation Reduction Act on Part D cost sharing.

Management Comments

• Our vision is to empower every physician with the technology to identify, manage, and treat chronic diseases earlier.
• Our strategy is to improve the care of people with Medicare, develop wide physician networks, and provide technology to help empower physicians.
• We believe the use of Clover Assistant and related data insights allows us to improve clinical decision-making through a highly scalable platform.
• We strongly believe in providing our members provider choice, and we consider our PPO plans to be our flagship insurance product.
• Counterpart Health is complementary to Clover Health, and enables us to deploy and expand the reach of our existing technology asset for new potential growth and high margin business opportunities, with low startup costs.

Industry Context

Clover Health operates in the highly competitive and rapidly changing U.S. Medicare Advantage market. The company's strategy to leverage technology like Clover Assistant and Counterpart Assistant aligns with broader industry trends towards data-driven healthcare and value-based care models. However, the industry is heavily influenced by regulatory changes, such as those from CMS and the Inflation Reduction Act, and faces ongoing pressures related to medical cost trends and Star Ratings, which are critical for plan attractiveness and reimbursement. The downgrade of Clover's primary PPO plans to 3.5 Stars highlights the intense competition and regulatory scrutiny within the Medicare Advantage space, where Star Ratings directly impact future revenue and market positioning.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks or industry standards beyond general statements about the competitive environment.

Legal Proceedings

• The SEC investigation related to certain disclosures and aspects of the business, including the Hindenburg Article, concluded on September 26, 2024, with the Staff not intending to recommend an enforcement action against the company.
• A securities class action lawsuit (Bond v. Clover Health Investments, Corp. et al.) was settled for $22 million on October 3, 2023, and dismissed with prejudice. The company used $19.5 million in insurance proceeds to fund the settlement.

Related Party Transactions

• CarePoint Health System (IJKG Opco LLC, Hudson Hospital Opco, LLC, Hoboken University Medical Center Opco LLC) is no longer deemed a related party as of May 22, 2025, following its emergence from Chapter 11 bankruptcy and transfer of assets to Hudson Regional Hospital.
• The company continues to contract with Medical Records Exchange, LLC (d/b/a Credo), an entity in which Vivek Garipalli (Executive Chairman and significant stockholder) has an indirect interest, for administrative services related to medical records retrieval. Expenses were $0.1 million for Q3 2025 and $0.4 million for the nine months ended September 30, 2025.
• The company continues its agreement with Thyme Care, Inc., an oncology care management company, where Vivek Garipalli is a board member and holds an equity interest. Expenses were $1.9 million for Q3 2025 and $6.1 million for the nine months ended September 30, 2025.
• The company entered into a Master Services Agreement in July 2025 with Guidehealth, LLC, where Thomas Tran (Board Director and Audit Committee Chair) serves as a director and holds an ownership interest. Expenses were $0.3 million for Q3 2025 and the nine months ended September 30, 2025.
• The company holds a non-controlling equity investment in Character Biosciences, which is considered a related party due to Vivek Garipalli serving on its Board of Directors. The investment was transitioned to fair value measurement (Level 3) at $11.3 million as of September 30, 2025, following a loss of significant influence.

Stakeholder Impact

• Shareholders: Negative impact due to widening net losses, significant declines in Adjusted EBITDA and Adjusted Net Income, and the PPO Star Rating downgrade, which could pressure future stock performance.
• Members: The downgrade of PPO Medicare Advantage plans to 3.5 Stars for 2026 may affect the attractiveness of these plans and potentially lead to changes in benefits or higher out-of-pocket costs in future years.
• Employees: Salaries and benefits decreased due to lower variable incentive bonus accruals, though base salaries increased with headcount growth. Prior restructuring initiatives concluded by December 31, 2024.
• Providers: Continued focus on empowering physicians with Clover Assistant technology aims to improve care delivery and outcomes.
• Creditors/Investors: Deteriorating profitability metrics and reduced cash from operations may raise concerns about financial health and ability to meet future obligations, despite current liquidity levels.

Next Steps

• Continue to develop and manage the Insurance business, focusing on Medicare Advantage plans.
• Maintain and increase adoption and use of Clover Assistant, including expanding Counterpart Assistant for external payors and providers.
• Monitor and manage the impact of the 2026 CMS Star Rating downgrade on PPO plans for the 2027 payment year.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06, ASU 2025-07) on consolidated financial statements and disclosures in future periods.

Key Dates

Recommendation

The company's financial performance shows significant deterioration, with net losses widening substantially, and key profitability metrics like Adjusted EBITDA and Adjusted Net Income experiencing sharp declines. The worsening net benefits expense ratio indicates increasing medical costs relative to premiums. Most critically, the downgrade of the PPO Medicare Advantage plans to 3.5 Stars for 2026 will negatively impact future payment streams for the vast majority of its members, posing a severe headwind to revenue and profitability. While membership and gross revenue are growing, the underlying economics are moving in the wrong direction, and the Star Rating downgrade signals fundamental challenges to the business model's sustainability and attractiveness. This combination of factors suggests a strong negative outlook for the stock.

Keywords

Medicare Advantage, Health Insurance, HealthTech, Clover Assistant, Counterpart Health, CMS Star Ratings, Q3 2025 Earnings, Financial Results, Healthcare Technology, PPO, HMO, Medical Loss Ratio